CANF - Can-Fite BioPharma Ltd.

NYSE American - Nasdaq Real Time Price. Currency in USD
3.2100
-0.0900 (-2.73%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close3.3000
Open3.2800
Bid3.1500 x 3200
Ask3.3000 x 1000
Day's Range3.1500 - 3.2800
52 Week Range2.6600 - 25.9500
Volume41,157
Avg. Volume253,009
Market Cap10.239M
Beta (3Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-4.8000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • Benzinga10 days ago

    Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm

    Can-Fite BioPharma (NYSE: CANF ) 6-K shows the company filed an appeal with the Supreme Court of Israel of a decision related to the convening of a special shareholder meeting to replace directors. On ...

  • All You Need to Know About Can-Fite (CANF) Rating Upgrade to Strong Buy
    Zackslast month

    All You Need to Know About Can-Fite (CANF) Rating Upgrade to Strong Buy

    Can-Fite (CANF) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Business Wire2 months ago

    Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019

    Can-Fite’s near term milestones include announcing top line results from its Phase II study of Namodenoson in the treatment of NAFLD/NASH. The Company currently has out-licensing agreements in several territories and has received approximately $17 million in upfront and milestone payments to date.

  • Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session
    Business Wire2 months ago

    Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session

    Phase III study protocol for Namodenoson in the treatment of advanced liver cancer patients is now being prepared and will be presented to FDA in an End of Phase II meeting

  • Business Wire2 months ago

    Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update

    PETACH TIKVA, Israel-- -- Preparatory work for an end-of-Phase II FDA meeting to initiate a Phase III study in liver cancer is ongoing Top-line data from Phase II NASH study with Namodenoson expected in H2 2019 Patient enrollment continues in two Phase III studies for Piclidenoson in the treatment of rheumatoid arthritis and psoriasis Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline ...

  • Benzinga2 months ago

    Secondary Offerings Put A Pause On May's Momentum

    During Thursday’s recap, I touched on why I think an excess of secondary offerings might be part of the reason for the faltering momentum. Four of the stocks I traded in the week, Can Fite Biopharma ADR (NYSE: CANF), Obalon Therapeutics Inc. (NASDAQ: OBLN), MYnd Analytics Inc. (NASDAQ: MYND) and OncoSec Medical Inc. (NASDAQ: ONCS) each announced a secondary offering. The net effect of these offerings is more share supply, less demand and a growing reticence amongst traders to buy into cheaper stocks like CANF and OBLN for fear of getting caught in a news halt and losing their shirts.

  • Business Wire2 months ago

    The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin

    ICFL 2019 is focused on the clinical needs and best practices for diagnosing and treating fatty liver disease to address the challenges and long-term effects of this disease. ICFL 2019 will feature leading experts across the relevant fields to educate and foster knowledge exchange.

  • GlobeNewswire2 months ago

    Can-Fite BioPharma Announces $6 Million Registered Direct Offering

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with certain institutional investors to receive gross proceeds of $6 million. In connection with the offering, the Company will issue 1,500,000 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $4.00 per ADS in a registered direct offering.  Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase one ADS.  The warrants will have an exercise price of $4.00 per ADS, will be immediately exercisable and will expire five and one-half years from the issuance date.  The closing of the offering is expected to take place on or about May 22, 2019, subject to the satisfaction of customary closing conditions.

  • Benzinga2 months ago

    Can-Fite Abstract Selected For Liver Conference

    Shares of the biotech  Can-Fite Biopharma Ltd (NASDAQ: CANF ) were skyrocketing Monday after an abstract describing data from the company's liver cancer study of the drug namodenoson was selected by the ...

  • Business Wire2 months ago

    Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)

    PETACH TIKVA, Israel-- -- The International Liver Cancer Association Annual Conference has selected the Can-Fite abstract for presentation Phase III trial for Namodenoson in advanced liver cancer is now under preparation Namodenoson has both Fast Track status and Orphan Drug designation from the U.S. FDA Can-Fite BioPharma Ltd . , a biotechnology company with a pipeline of proprietary small molecule ...

  • Business Wire2 months ago

    Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it is conducting preparatory work for a planned pivotal Phase III study of its drug candidate Namodenoson in the treatment of advanced liver cancer in patients as a first line and second line treatment. Namodenoson was found to increase overall survival in hepatocellular carcinoma (HCC) patients with Child Pugh B7, the largest subpopulation of the study, as compared to placebo, even though the trial did not meet its primary endpoint.

  • Business Wire3 months ago

    Can-Fite Announces ADS Ratio Change

    On the effective date, each ADS holder will be required to exchange every fifteen (15) ADSs then held for one (1) new ADS. The Bank of New York Mellon, the depositary bank, will arrange for the exchange of the current ADSs for the new ones.

  • Business Wire3 months ago

    Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea

    Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it has received a $1,000,000 payment from Chong Kun Dang Pharmaceuticals (CKD) (Korean Stock Exchange: 185750.KS) of South Korea. CKD has licensed the distribution rights to Namodenoson in South Korea for the treatment of liver cancer and non-alcoholic steatohepatitis (NASH) in a deal totaling $6,000,000 in upfront and milestone payments, plus a transfer price for delivering finished products to CKD.

  • Business Wire3 months ago

    Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting

    PETACH TIKVA, Israel-- -- Acceptance for late breaking oral presentation underscores the oncology community’s interest in Namodenoson as a potential treatment for liver cancer Can-Fite now preparing for Phase III study of Namodenoson in patients with advanced liver cancer Child Pugh B 7 cirrhosis with Key Opinion Leader as Principal Investigator Can-Fite BioPharma Ltd . , a biotechnology company with ...

  • Business Wire4 months ago

    Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with certain institutional investors to receive gross proceeds of approximately $3.2 million. In connection with the offering, the Company will issue 4,923,078 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $0.65 per ADS in a registered direct offering.

  • Business Wire4 months ago

    Can-Fite Files Annual Report for the Year Ended December 31, 2018

    Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S.

  • Business Wire4 months ago

    Can-Fite Reports 2018 Financial Results & Provides Clinical Update

    PETACH TIKVA, Israel-- -- Global distribution deals signed in Europe and China, including Can-Fite’s largest deal to date for up to $74.5 M Top-line data from Phase II Namodenoson trial in the treatment of liver cancer supports continuation into Phase III study Top-line Data from Phase II NASH Study with Namodenoson expected in H2 2019 Patient enrollment continues in two Phase III studies for Piclidenoson ...

  • Business Wire4 months ago

    Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson

    The study did not achieve its primary end point of median overall survival in the whole population of 78 patients, however, superiority in median overall survival was found in the largest study subpopulation of 56 patients and in secondary end points including objective response in the whole population, strongly supporting the progression into Phase III.

  • ACCESSWIRE4 months ago

    Four Marijuana Stocks on the Rise on Wednesday

    Whereas in the past, society largely condemned cannabis and refused to consider the potential benefits of investing in cannabis and/or utilizing cannabis products, those feelings are slowly dissipating. The positive shift in public opinion can be attributed to the fact that the medical community has released data supporting the use of cannabidiol as a form of alternative treatment, given its effectiveness as an anti-inflammatory. Like other sectors whirring with innovation, the cannabis industry is rapidly progressing into the future and, rather than be left behind, investors looking for potential opportunities may want to keep cannabis companies on their radars.

  • Business Wire5 months ago

    Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the Company’s VP of Business Development, Sari Fishman will participate in the Bio Asia International Conference in Tokyo, Japan on March 5th and 6th, 2019. The BIO Asia International Conference brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments.

  • Business Wire5 months ago

    Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the expansion of its distribution agreement with Chong Kun Dang Pharmaceuticals (CKD) (Korean Stock Exchange: 185750.KS) in South Korea, for the indication of non-alcoholic steatohepatitis (NASH).

  • ACCESSWIRE5 months ago

    Watch These 4 Healthcare Stocks Set The Pace On Monday (2/4/19)

    Over time, in an effort to further these advancements in the healthcare industry, legislators have sought to pass positive legislation in favor of legalizing marijuana, resulting in the passing of the US Farm Bill as well as other laws around the world. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Can-Fite BioPharma Ltd (CANF), BioLineRx Ltd (BLRX), and Aurora Cannabis Inc., (ACB) represent four cannabis companies determined to develop nuanced approaches for integrating cannabis as a means for improving the quality of life for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • Business Wire5 months ago

    Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug

    Osteoarthritis is a common joint disease impacting ageing populations and represents an $8 billion global treatment market in 2017 and is expected to rise to $11.6 billion by the end of 2025 according to Persistence Market Research.

  • ACCESSWIRE6 months ago

    4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)

    With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Co-Diagnostics Inc (CODX), Can-Fite BioPharma Ltd (CANF), and Eyenovia Inc (EYEN) represent four healthcare companies determined to develop and distribute the best quality healthcare options for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • Business Wire6 months ago

    Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

    Can-Fite’s Piclidenoson, a Phase III drug candidate, and Namodenson, a Phase II drug candidate, both target the A3 adenosine receptor (A3AR), which the Company believes may treat cytokine release syndrome (CRS) while also promoting an anti-cancer effect.